Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share from the same period last year.
Related Posts
Why Beam Global Stock Is Charging Higher After Hours
Beam Global (NASDAQ: BEEM) shares are trading higher after the close Monday on the heels of the company's first-quarter report.
Zai Lab: Q1 Earnings Insights
Zai Lab (NASDAQ:ZLAB) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM. Here’s what…
Investment Chief Proposes Adding Warren Buffett’s Berkshire Hathaway To ‘Magnificent Seven’
The investment chief of a wealth consulting group suggests expanding a group of seven large-cap growth stocks to incorporate Berkshire Hathaway.